Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 10Phase 1/2 7Phase 3 2Phase NA 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 43Leukemia 7Myelodysplastic Syndromes 4Leukemia, Myelomonocytic, Chronic 4Recurrence 2Pathologic Complete Response 2Neoplasms 2MDS 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Higher-risk Myelodysplastic Syndrome 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Dexamethasone 28Rituximab 16pomalidomide 13Gemcitabine 12Lenalidomide 11Cisplatin 11Bortezomib 11Paclitaxel 10Cyclophosphamide 8Carboplatin 8carfilzomib 7selinexor 5daratumumab 5Drug Therapy 5Doxorubicin 5Cytarabine 5ibrutinib 4Vincristine 4Temozolomide 4Prednisone 4Docetaxel 4Calcium Dobesilate 4Bevacizumab 4Aspirin 4tisagenlecleucel 3Cetuximab 3Bendamustine Hydrochloride 3venetoclax 2ofatumumab 2galiximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Recurrence × Azacitidine × Clear all
NCT03765541 2025-04-10

DEXAML-03

University Hospital, Toulouse

Phase 3 Terminated
73 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04722952 2021-12-03

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML

The First Affiliated Hospital of Soochow University

Phase 3 Unknown
30 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡